Kezar Life Sciences (KZR) repays $6.3M, terminates loan

Kezar Life Sciences (KZR) repaid its debt under a prior loan agreement and terminated the facility.

Rhea-AI Filing Summary

Kezar Life Sciences (KZR) repaid its debt under a prior loan agreement and terminated the facility. On October 20, 2025, the company used cash on hand to repay $6.3 million, covering the aggregate outstanding amount, accrued interest, and exit fees under its November 4, 2021 Loan and Security Agreement with Oxford Finance LLC and related lenders. Following repayment, the agreement was terminated and all liens and security interests were released.

This action removes obligations tied to the loan and releases collateral, simplifying Kezar’s capital structure.

Insights

Capital structure analyst

Debt fully repaid; facility terminated and liens released.

Kezar Life Sciences repaid $6.3 million on October 20, 2025 using cash on hand, satisfying all amounts due under its Loan and Security Agreement. The agreement was then terminated and all liens and security interests were released.

Eliminating this borrowing removes the company’s obligations under the facility and clears pledged collateral. The filing does not discuss new financing or replacement debt.

Key facts are the repayment amount, the use of cash on hand, the counterparties (Oxford Finance LLC and lenders), and the termination with lien release; any future funding plans are not addressed in this excerpt.

8-K Event Classification

Item 1.02 — Termination of a Material Definitive Agreement

1 item

Item 1.02 Termination of a Material Definitive Agreement Business

A significant contract was terminated, which may affect business operations or revenue.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kezar Life Sciences (KZR) announce in this 8-K?

Kezar Life Sciences repaid $6.3 million to fully satisfy its Loan and Security Agreement and terminated the facility.

When did KZR complete the loan repayment and termination?

The repayment occurred on October 20, 2025, after which the agreement was terminated.

How did Kezar fund the repayment?

The company used cash on hand to make the repayment.

Who were the counterparties to the loan agreement?

The agreement was with Oxford Finance LLC as collateral agent and the lenders party thereto.

What happened to liens and security interests after repayment?

All liens and security interests granted under the loan were released.

When was the original Loan and Security Agreement signed?

It was dated November 4, 2021.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/22/2025 - 04:19 PM Learn about SEC filing dates

false000164566600016456662025-10-202025-10-200001645666us-gaap:CommonStockMember2025-10-202025-10-200001645666kzr:PreferredSharePurchaseRightsMember2025-10-202025-10-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________________

FORM 8-K

__________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2025

__________________________________________________________

Kezar Life Sciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

__________________________________________________________

Delaware			001-38542			47-3366145
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
4000 Shoreline Court, Suite 300 South San Francisco, California						94080
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 822-5600

(Former Name or Former Address, if Changed Since Last Report)

__________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

KZR

The Nasdaq Stock Market LLC

Preferred Share Purchase Rights

N/A

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 1.02 Termination of a Material Definitive Agreement.

On October 20, 2025, Kezar Life Sciences, Inc. (the “Company”), using cash on hand, made a repayment of $6.3 million in full satisfaction of the aggregate outstanding amount, including accrued interest and exit fees as of such date, under the Loan and Security Agreement (the “Loan Agreement”), dated as of November 4, 2021, among the Company, as borrower, Oxford Finance LLC, as collateral agent, and the lenders party thereto. The Loan Agreement was terminated in accordance with the terms of a payoff letter and all liens and security interests granted thereunder to secure the obligations were released.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									KEZAR LIFE SCIENCES, INC.
Date:			October 22, 2025			By:			/s/ Marc L. Belsky
									Marc L. Belsky Chief Financial Officer and Secretary